KR101317131B1 - 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법 - Google Patents

정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법 Download PDF

Info

Publication number
KR101317131B1
KR101317131B1 KR1020077007738A KR20077007738A KR101317131B1 KR 101317131 B1 KR101317131 B1 KR 101317131B1 KR 1020077007738 A KR1020077007738 A KR 1020077007738A KR 20077007738 A KR20077007738 A KR 20077007738A KR 101317131 B1 KR101317131 B1 KR 101317131B1
Authority
KR
South Korea
Prior art keywords
acetic acid
less
hydrobromic acid
metal ion
acid solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077007738A
Other languages
English (en)
Korean (ko)
Other versions
KR20070059137A (ko
Inventor
벤-자이온 돌리츠키
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101317131(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20070059137A publication Critical patent/KR20070059137A/ko
Application granted granted Critical
Publication of KR101317131B1 publication Critical patent/KR101317131B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020077007738A 2004-09-09 2005-09-09 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법 Expired - Lifetime KR101317131B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60884304P 2004-09-09 2004-09-09
US60/608,843 2004-09-09
PCT/US2005/032395 WO2006029393A2 (en) 2004-09-09 2005-09-09 Process for preparation of mixtures of polypeptides using purified hydrobromic acid

Publications (2)

Publication Number Publication Date
KR20070059137A KR20070059137A (ko) 2007-06-11
KR101317131B1 true KR101317131B1 (ko) 2013-10-10

Family

ID=36037047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077007738A Expired - Lifetime KR101317131B1 (ko) 2004-09-09 2005-09-09 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법

Country Status (27)

Country Link
US (2) US7495072B2 (enExample)
EP (3) EP2177528B1 (enExample)
JP (1) JP5149008B2 (enExample)
KR (1) KR101317131B1 (enExample)
CN (1) CN101166754B (enExample)
AT (2) ATE454396T1 (enExample)
AU (1) AU2005282249B2 (enExample)
BR (1) BRPI0515033B1 (enExample)
CA (1) CA2579656C (enExample)
CY (1) CY1110280T1 (enExample)
DE (1) DE602005018800D1 (enExample)
DK (3) DK1799703T3 (enExample)
ES (3) ES2382298T3 (enExample)
HR (3) HRP20100164T1 (enExample)
IL (2) IL181596A (enExample)
IS (1) IS8622A (enExample)
MX (1) MX2007002760A (enExample)
NO (1) NO20071632L (enExample)
NZ (1) NZ554018A (enExample)
PL (3) PL2177528T3 (enExample)
PT (3) PT2177528E (enExample)
RS (3) RS53248B (enExample)
RU (1) RU2388764C2 (enExample)
SI (3) SI2177528T1 (enExample)
UA (1) UA91029C2 (enExample)
WO (1) WO2006029393A2 (enExample)
ZA (1) ZA200702591B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) * 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
JP2007535498A (ja) * 2004-03-03 2007-12-06 テバ ファーマシューティカル インダストリーズ リミティド グラチラマー・アセテートおよびリルゾールでの併用療法
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
SI2177528T1 (sl) 2004-09-09 2012-04-30 Teva Pharma Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
ZA200705874B (en) * 2005-02-02 2009-04-29 Teva Pharma Process for producing polypeptide mixtures using hydrogenolysis
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
EP2277050B2 (en) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
PL2307448T3 (pl) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
US8212002B2 (en) * 2008-08-07 2012-07-03 Scinopharm Taiwan Ltd Synthesis of glatiramer acetate
ES2523732T5 (es) 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
KR20140061559A (ko) 2009-08-20 2014-05-21 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2797227A1 (en) * 2010-04-27 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of polypeptides and salts thereof
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
US8788046B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
US9029507B2 (en) * 2011-02-14 2015-05-12 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
JP5701103B2 (ja) * 2011-03-02 2015-04-15 昭和シェル石油株式会社 潤滑油のための消泡剤組成物及びそれを用いた消泡方法
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN102717992A (zh) * 2012-05-30 2012-10-10 苏州市旭洋工业搪瓷厂 一种搪玻璃溴素贮罐
CN102718963B (zh) * 2012-06-19 2014-10-15 深圳翰宇药业股份有限公司 聚合物多肽的制备方法
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3062792A1 (en) 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503735A (ja) * 1995-04-14 1999-03-30 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド Ｇｖｈｄ防止用合成ペプチドコポリマーからなる医薬組成物
US20040091956A1 (en) * 2002-11-13 2004-05-13 Elena Bejan Process for the preparation of polypeptide 1

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS54119499A (en) * 1978-03-09 1979-09-17 Shionogi & Co Ltd Triazolobenzodiazepin derivative
JPS6053535A (ja) * 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AU596986B2 (en) 1985-06-18 1990-05-24 Emory University Biologically-active copolymers
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
RU2198900C2 (ru) * 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Усовершенствованный сополимер-1 и способ его получения
FR2750423B1 (fr) 1996-06-28 1998-08-14 Rhone Poulenc Chimie Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ID23991A (id) 1997-09-30 2000-06-14 Daiichi Seiyaku Co Turunan-turunan sulfonil
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en) 1997-10-24 1999-10-12 Steag Ast Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000027417A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US6114649A (en) 1999-07-13 2000-09-05 Duran Technologies Inc. Anode electrode for plasmatron structure
AU7343800A (en) 1999-09-03 2001-04-10 Quorum Sciences, Inc. Quorum sensing signaling in bacteria
DE19944003C1 (de) 1999-09-14 2001-03-22 Baumeister & Ostler Gmbh Co Faltbare Trenneinrichtung
MXPA02007106A (es) * 2000-01-20 2002-12-13 Mcinnis Patricia A El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para terapia neuroprotectora.
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
ES2256200T3 (es) 2000-06-07 2006-07-16 Yeda Research And Development Co., Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato.
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja) 2000-11-10 2005-09-21 ヤマウチ株式会社 シュープレス用ベルト
MXPA03004458A (es) * 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
JP3661935B2 (ja) 2001-06-20 2005-06-22 ソニー株式会社 情報処理装置および方法、記録媒体、並びにプログラム
CA2469393C (en) * 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
AU2003301457A1 (en) 2002-05-09 2004-05-04 Keith Baumann Bioweapon-detecting fibrous-network products and methods for making same
EP1565486A2 (en) * 2002-11-13 2005-08-24 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
DE10353960B4 (de) 2003-10-16 2006-03-23 Vertilas Gmbh Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
EP1797109B1 (en) * 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
SI2177528T1 (sl) 2004-09-09 2012-04-30 Teva Pharma Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline
ZA200705874B (en) * 2005-02-02 2009-04-29 Teva Pharma Process for producing polypeptide mixtures using hydrogenolysis
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007072865A1 (ja) 2005-12-22 2007-06-28 Pioneer Corporation 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503735A (ja) * 1995-04-14 1999-03-30 イエダ リサーチ アンド デベロツプメント カンパニー リミテツド Ｇｖｈｄ防止用合成ペプチドコポリマーからなる医薬組成物
US20040091956A1 (en) * 2002-11-13 2004-05-13 Elena Bejan Process for the preparation of polypeptide 1

Also Published As

Publication number Publication date
EP2361924B1 (en) 2013-12-11
EP1799703A4 (en) 2008-09-03
EP1799703B1 (en) 2010-01-06
CN101166754A (zh) 2008-04-23
IL181596A (en) 2015-10-29
PL2361924T3 (pl) 2014-08-29
RU2388764C2 (ru) 2010-05-10
IS8622A (is) 2007-03-16
SI1799703T1 (sl) 2010-04-30
US20060052586A1 (en) 2006-03-09
HK1140775A1 (en) 2010-10-22
EP1799703A2 (en) 2007-06-27
UA91029C2 (uk) 2010-06-25
CN101166754B (zh) 2014-04-23
EP2177528A1 (en) 2010-04-21
AU2005282249B2 (en) 2012-08-02
KR20070059137A (ko) 2007-06-11
RS51257B (sr) 2010-12-31
ATE454396T1 (de) 2010-01-15
ZA200702591B (en) 2009-03-25
EP2361924A1 (en) 2011-08-31
DE602005018800D1 (de) 2010-02-25
ES2338138T3 (es) 2010-05-04
CY1110280T1 (el) 2015-01-14
DK2361924T3 (en) 2014-03-10
IL181596A0 (en) 2007-07-04
PT1799703E (pt) 2010-03-04
PL1799703T3 (pl) 2010-06-30
PL2177528T3 (pl) 2012-09-28
JP2008512494A (ja) 2008-04-24
SI2177528T1 (sl) 2012-04-30
US20070021324A1 (en) 2007-01-25
PT2177528E (pt) 2012-03-19
IL241702A0 (en) 2015-11-30
AU2005282249A1 (en) 2006-03-16
DK2177528T3 (da) 2012-03-26
ES2451006T3 (es) 2014-03-26
HK1100780A1 (en) 2007-09-28
MX2007002760A (es) 2007-05-18
NZ554018A (en) 2009-06-26
CA2579656C (en) 2014-11-04
NO20071632L (no) 2007-06-05
WO2006029393A3 (en) 2007-12-13
RU2007112956A (ru) 2008-10-20
BRPI0515033A (pt) 2008-07-01
WO2006029393A8 (en) 2007-04-19
HRP20140216T1 (hr) 2014-06-06
ATE536363T1 (de) 2011-12-15
US7495072B2 (en) 2009-02-24
BRPI0515033B1 (pt) 2021-05-25
HK1156637A1 (en) 2012-06-15
ES2382298T3 (es) 2012-06-07
SI2361924T1 (sl) 2014-04-30
EP2177528B1 (en) 2011-12-07
PT2361924E (pt) 2014-03-13
RS53248B (sr) 2014-08-29
CA2579656A1 (en) 2006-03-16
HRP20100164T1 (hr) 2010-07-31
HRP20120209T1 (hr) 2012-06-30
WO2006029393A2 (en) 2006-03-16
JP5149008B2 (ja) 2013-02-20
DK1799703T3 (da) 2010-04-19
RS52265B (sr) 2012-10-31
BRPI0515033A8 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
KR101317131B1 (ko) 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
CN103520735B (zh) 包含非天然编码的氨基酸的人生长激素配方
Brennan et al. Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl‐and aspartyl‐containing peptides
JP7671251B2 (ja) Ｆｍｏｃ骨格を有する保護基で保護されたアミノ基含有化合物の定量法
Strosberg et al. Amino acid sequence of rabbit pneumococcal antibody. I. Light-chain cysteine-containing peptides
Hegyi et al. Gln‐41 is intermolecularly cross‐linked to Lys‐113 in F‐actin by N‐(4‐azidobenzoyl)‐putrescine
Hamm et al. Deciphering Polymer Interactions in Bioconjugates with Different Architectures by Structural Analysis via Time‐Resolved Limited Proteolysis Mass Spectrometry
HK1100780B (en) Process for preparation of mixtures of polypeptides using purified hydrobromic acid
HK1156637B (en) Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
HK1140775B (en) Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
Hecht et al. Helix-Coil Stability Constants for the Naturally Occurring Amino Acids in Water. 17. Threonine Parameters from Random Poly (hydroxylbutylglutamine-co-L-threonine)
Barden et al. Fluorine-19 NMR study of the myosin and tropomyosin binding sites on actin
CN104098655B (zh) 用于合成醋酸格拉替雷的质谱内标的多肽
Slobin et al. Limited cleavage of eukaryotic elongation factor Tu by trypsin: alignment of the tryptic fragments and effect of nucleic acids on the enzymatic reaction
US20220025115A1 (en) Methods for Measuring Consumption of Amino Acid N-Carboxyanhydrides during Manufacture of Glatiramer Acetate
JP2014532692A (ja) ランダムポリペプチドの調製プロセス、及び、酢酸ガラティラメルを製造するためのガイダンスツールとして円偏光二色性を用いること

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20160922

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170922

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180921

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000